Isomorphic Labs, an AI-driven drug discovery company spun out of Google DeepMind, is reportedly in advanced talks to raise over $2 billion in a new funding round. Thrive Capital, which led Isomorphic Labs' initial funding, is expected to spearhead this round, with Alphabet also participating. This follows a period where Sinovac Biotech reported a slight increase in sales but a net loss due to asset impairment charges, while also securing its Nasdaq listing. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT Accelerates AI's role in drug discovery, potentially leading to faster development of new therapeutics.
RANK_REASON Significant funding round for an AI-driven drug discovery company.